Biologically selective potassium channel openers having 1,1- diethylpropyl group

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 23, 1998, Pages 3397-3402

  Yoshiizumi, Kazuya ^a   Seko, Norihiko ^a   Nishimura, Noriyasu ^a   Ikeda, Shoji ^a   Yoshino, Kohichiro ^a   Kondo, Hirosato ^a   Tanizawa, Kazutaka ^b  

^a KANEBO LTD   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CROMAKALIM; PINACIDIL; POTASSIUM CHANNEL AFFECTING AGENT; PROPANE;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; DRUG SYNTHESIS; MEMBRANE POTENTIAL; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; URINARY EXCRETION;

EID: 0032401163     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00625-8     Document Type: Article

References (18)

1. 1. a) Kolb, H. A. Rev. Physiol. Biochem. Pharmacol., 1990, 15, 51.
2. b) Hamilton, T. C.; Weir, S. W.; Weston, A. H. Br. J. Pharmacol., 1986, 88, 103.
3. 2. Atwal, K. S. Med. Res. Rev., 1992, 12, 569.
4. 3. a) Longman, S. D.; Hamilton, T. C. Med. Res. Rev., 1992,12, 73.
5. b) Gopalakrishman, M.; Janis, R. A.; Triggle, D. J. Drug Dev. Res., 1993, 28, 95.
6. 4. Petersen, H. J.; Nielsen, C. K.; Arrigoni-Martelli, E. J. Med. Chem., 1978, 21, 773.
7. 5. Ashwood, V. A; Buckingham, R. E.; Cassidy, F.; Evans, J. M., Frauk, E. A; Hamilton, T. C.; Nash, D. J.; Stemp, G.; Willcocks, K. J. J. Med. Chem., 1986, 29, 2194.
8. 6. a) Edward, G.; Henshaw, M.; Miller, M.; Weston, A. H. Br. J. Pharmacol., 1991, 102, 679.
9. b) Atwal, K. S. Drug Dev. Res., 1994, 33, 250.
10. 7. a) Atwal, K. S.; Graver, G. J.; Ahmed, S. Z.; Ferrara, F. W.; Harper, T. W.; Kim, K. S.; Sleph, P. G; Dzwonczyk, S.; Russell, A D.; Moreland, S.; McCullough, J. R.; Normandin, D. E. J. Med. Chem., 1993, 36, 3971.
11. b) Ohnmacht, C. J.; Russell, K.; Empfield, J. R.; Gibson, K. H.; Mayhugh, D. R.; McLaren, F. M.; Shapiro, H. S.; Brown, F. J.; Trainor, D. A.; Ceccarelli, C.; Lin, M. M.; Masek, B. B.; Forst, J. M.; Harris, R. J.; Hulsizer, J. M.; Lewis, J. J.; Silver-man, S. M.; Smith, R. W.; Warwick, P.J.; Kau, S.T.; Chun, A. L.; Grant, T. L.; Howe, B. B.; Li, J. H.; Trivedi, S.; halterman, T. J.; Yochim, C.; Dyrofl, M. C.; Kirkland, M.; Neilson, K. L. J. Med. Chem., 1996, 39, 3971
12. 8. a) Bray, K. M.; Newgreen, D. T.; Small, R. C.; Southerton, J. S.; Taylor, S. G.; Weir, S. M.; Weston, A. H. Br. J. Pharmacol., 1987, 91, 412.
13. b) Cook, N. S., Quast, U.; Hof, R. P.; Baumlin, Y.; Pally, C. J. Cardiovasc. Pharmacol., 1988, 11, 90.
14. 9. Yoshiizumi, K.; Ikeda, S.; Goto, K.; Morita, T.; Nishimura, N.; Sukamoto, T.; Yoshino, K. Chem. Pharm. Bull., 1996, 44, 2042.
15. 6) δ:5.73(2H, bs), 6.2-6.4(1H, m), 6.4-6.7(2H, m). 12. n=20 for pinacidil, n=5 for cromakalim, 1, and 2a-h. For details, see experimental section in References and Notes 9.
16. 50) as determined by linear regression analysis. n=4 for 2c-2e, and 2h, n=5 for the others.
17. 50) as determined by linear regression analysis. n=5 for all the tested compounds.
18. 15. For details, see : Yoshiizumi, K.; Ikeda, S.; Nishimura, N.; Yoshino, K. Chem. Pharm. Bull., 1997, 45, 2005.